Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Dosing Guide
How to Take Cagrilintide
For Weight Management (Monotherapy)
Starting Dose:
- 0.3 mg subcutaneously once weekly for 4 weeks
- Note: This initial dose helps minimize gastrointestinal side effects
Dose Escalation Schedule:
- Week 1-4: 0.3 mg weekly
- Week 5-8: 0.6 mg weekly
- Week 9-12: 1.2 mg weekly
- Week 13-16: 2.4 mg weekly
- Week 17+: Continue 2.4 mg weekly (maintenance dose)
Alternative High-Dose Protocol (Research):
- Can escalate up to 4.5 mg weekly if tolerated
- Shown to be more effective than liraglutide 3.0 mg daily
How to Take It:
- Once-weekly subcutaneous injection
- Same day each week, with or without food
- Rotate injection sites (abdomen, thigh, upper arm)
For Combination Therapy (CagriSema)
Co-administration with Semaglutide:
- Both medications given as separate weekly injections
- Co-escalated together over 16-20 weeks
Dose Escalation Schedule:
- Week 1-4: Cagrilintide 0.25 mg + Semaglutide 0.25 mg
- Week 5-8: Cagrilintide 0.5 mg + Semaglutide 0.5 mg
- Week 9-12: Cagrilintide 1.0 mg + Semaglutide 1.0 mg
- Week 13-16: Cagrilintide 1.7 mg + Semaglutide 1.7 mg
- Week 17+: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Clinical Trial Results:
- CagriSema 2.4/2.4 mg: Average 20.4% weight loss at 68 weeks
- 60% of patients achieved ≥20% weight loss
- 23% achieved ≥30% weight loss
For Type 2 Diabetes
Dosing Protocol:
- Same escalation as weight management
- Target dose: 2.4 mg weekly
- Monitor blood glucose closely during titration
- May require diabetes medication adjustments
Dosing Calculators
Dose Calculator
Unit Converter
Quick Reference:
How to Take Cagrilintide
A. For Weight Management (Monotherapy)
Starting Dose:
0.3 mg subcutaneously once weekly for 4 weeks
Note: This initial dose helps minimize gastrointestinal side effects
Dose Escalation Schedule:
Alternative High-Dose Protocol (Research):
- Can escalate up to 4.5 mg weekly if tolerated
- Shown to be more effective than liraglutide 3.0 mg daily
How to Take It:
- Once-weekly subcutaneous injection
- Same day each week, with or without food
- Rotate injection sites (abdomen, thigh, upper arm)
B. For Combination Therapy (CagriSema)
Co-administration with Semaglutide:
- Both medications given as separate weekly injections
- Co-escalated together over 16-20 weeks
Dose Escalation Schedule:
Clinical Trial Results:
- CagriSema 2.4/2.4 mg: Average 20.4% weight loss at 68 weeks
- 60% of patients achieved ≥20% weight loss
- 23% achieved ≥30% weight loss
C. For Type 2 Diabetes
Dosing Protocol:
- Same escalation as weight management
- Target dose: 2.4 mg weekly
- Monitor blood glucose closely during titration
- May require diabetes medication adjustments
Dosing Calculators
Dose Calculator
Unit Converter
Quick Reference:
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.